Publication date: Oct 10, 2019
A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial. All subjects will be on a daily dose of metformin for a minimum of 3 months and a maximum of 9 months.
- A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
- Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis
- Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)
- Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®